methicillin-resistant Staph aureus (MRSA) infections in hospitalized patients

New guidelines will clarify treatment of methicillin-resistant Staph aureus (MRSA) infections in hospitalized patients.

Choose treatments based on the infection site, patient's age, antibiotic sensitivities, patient tolerance, cost, etc.

Keep in mind that the newer drugs (daptomycin, linezolid, telavancin) cost about $200 per day...ten times more than the older ones (clindamycin, TMP/SMX, vancomycin).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote